APOA1, a protein with multiple therapeutic functions, has been reported to be associated with an improved glycaemic control in patients with type 2 diabetes and a decelerated progression of prediabetes to type 2 diabetes [43–45]. This evidence concerns the gene APOA1 and type 2 diabetes mellitus.